Johnson & Johnson (NYSE:JNJ)’s Lung Cancer Initiative has signed a licensing and development accord to access narrow-spectrum Kinase inhibitors of Pulmatrix Inc (NASDAQ:PULM). As per the terms of the deal, Lung Cancer Initiative will initially pay an upfront amount of $7.2 million to Pulmatrix. The company will pay an additional amount of $2 million on […]
Lung Cancer Initiative
Recent Posts
Summary of Concussion
OMID Posts 2022 Annual Report and Provides Update
AmpliTech Records a New Benchmark at Satellite 2023 Show in Washington, D.C.
Premier Biomedical Inc. (OTC: BIEI), Welcomes Officers, Directors and Key Advisors
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
Popular Post
-
Sports Gambling and the Horse Racing Market
-
ZICIX+CTIP-FII RECEIVES NOTICE TO PROCEED FROM PROJECT OWNER TO START THE $20 MILLION SENIOR CITIZENS RESIDENCE PROJECT IN NEWARK, NEW JERSEY
-
Mass Megawatts Targets Solar Customers throughout the Northeast and its Solar Tracker’s Time of Use (TOU) Rates Advantages Become More Important When California’s NEM 3 Takes Effect Next Month
-
Principal Solar to Acquire Minerva-Rockdale Leases, Wells, and Assets
-
Kona Gold Beverage, Inc Announces its Ooh La Lemin Lemonades to be sold in Town Pump Convenience Stores in Montana
